

Un-Audited Financial Statements For the Nine months
and Three months ended September 30, 2026



 ABBOTT

Corporate Information

BOARD OF DIRECTORS

Ehsan Ali Malik (Chairman) (Non-Executive Director)

Syed Anis Ahmed (Chief Executive Officer)

Celestino Jacinto Dos Anjos (Non-Executive Director)

Ayla Majid (Independent Director)

Mohsin Ali Nathani (Independent Director)

Brian William Jordan (Non-Executive Director)

Seema Khan (Executive Director)

AUDIT COMMITTEE

Mohsin Ali Nathani (Chairman)

Ayla Majid

Celestino Jacinto Dos Anjos

HUMAN RESOURCE AND REMUNERATION COMMITTEE

Mohsin Ali Nathani (Chairman)

Ehsan Ali Malik

Syed Anis Ahmed

RISK MANAGEMENT COMMITTEE

Ayla Majid (Chairperson)

Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

SHARE TRANSFER COMMITTEE

Syed Anis Ahmed (Chairman)

Celestino Jacinto Dos Anjos

Seema Khan

BANKING COMMITTEE

Mohsin Ali Nathani (Chairman)

Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

NOMINATION COMMITTEE

Ehsan Ali Malik (Chairman)

Mohsin Ali Nathani

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Tabish Aseem

COMPANY SECRETARY

Muhammad Usama Jamil

CHIEF INTERNAL AUDITOR

Muhammad Ali Shiwani

AUDITORS

EY Ford Rhodes, Chartered Accountants

(a member firm of Ernst & Young Global Limited)

LEGAL ADVISORS

Orr, Dignam & Co.

Surridge & Beechono

BANKERS

Standard Chartered Bank (Pakistan) Limited

Deutsche Bank AG

Habib Bank Limited

National Bank of Pakistan

MCB Bank Limited

Faysal Bank Limited

Habib Metropolitan Bank

Citibank

SENIOR MANAGEMENT TEAM

Syed Anis Ahmed

(Chief Executive Officer)

Syed Tabish Aseem

(Chief Financial Officer)

Bilal Naseem

(Director Operations)

Asim Shafiq

(General Manager, Abbott Nutrition

International Pakistan)

Saad Siddique

(Country Manager, Abbott Diagnostics Division Pakistan)

Dr. Shaikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Asghar Huda

(Director Human Resource)

SHARE REGISTRAR

FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi.

FACTORY LOCATIONS

Plot No. 258 & 324, Opposite Radio

Pakistan Transmission Centre,

Hyderabad Road, Landhi, Karachi.

Plot No. 13, Sector 20,

Korangi Industrial Area, Karachi.

CITY OFFICE

11th and 12th Floors, Ocean Tower,
G-3, Block-9, Main Clifton Road, Karachi.

SALES OFFICES

House No. 25/III/B, Jamrud Lane,
University Town, Peshawar, Pakistan.

WAREHOUSES

Plot No. 136, Street # 9, Sector 1-10/3,
Industrial Area, Islamabad.

16 KM Shahpur Kanjan,
Multan Road, Lahore.

Hasanabad Gate # 2,
Near Pak Arab Fertilizers,
Khanewal Road, Multan.

WEBSITE

www.pk.abbott

Directors' Report

The Directors of your Company are pleased to present the un-audited condensed interim financial statements of your Company, for the nine months ended Sep 30, 2026.

FINANCIAL HIGHLIGHTS

For nine months' period ended September 30, 2026

Overall sales for the period increased by 4% over the same period last year. Pharmaceutical sales increased by 7% driven by the sustained performance of established brands, while Nutritional sales decreased by 5%. Diagnostics segment increased by 9% against same period last year.

Gross profit margin of your Company improved to 38% versus 34% during the same period last year mainly driven by cost optimization and various other efficiency measures taken across the Company as well as change in product mix. Gross margin for the pharmaceutical segment improved to 39% from 33%, whereas the gross margin for Nutritional segment decreased to 41% from 44%.

Selling and distribution expenses increased by 6% against the same period last year in line with growing operations and inflationary impacts. Tax charges increased on account of improved margins. Net profit as a percentage of sales was 11% for the period.

For third quarter ended September 30, 2026

Sales for the quarter increased by 4% over the same period last year. Pharmaceutical sales increased by 5% whereas sales for nutrition decreased by 2%.

Similar to the year-to-date results, gross profit margin of the Company improved to 38% from 34% during the same quarter last year.

Operating expenses decreased by 2% over the same period last year mainly on account of decrease in travelling and conveyance expenses amidst global travel issues. Other charges increased by Rs. 63 million (11%) over the same quarter last year due to increase in statutory charges owing to improved profitability.

Consequently, profit after tax for the quarter increased by Rs. 721 million vs. the same period last year.

FUTURE OUTLOOK

The Company continues to operate under a very fluid regulatory, fiscal and macro-economic landscape. It has required us to remain agile in our approach and execution. We welcome the changes surrounding nonessential drugs not listed in the National Essential Medicines List. However, there is still a need for a robust process of pricing reviews and adjustments for essential drugs, finalization of hardship cases and lower priced drug issues as well to ensure patients continue to have access to quality medications.

Current geopolitical tensions may still lead to some disruptions as they continue in to the final quarter. Persistent pressure on global oil prices could add to inflationary trends and weigh on demand, while also putting strain on foreign exchange conditions. We remain attentive to these developments and continue to adapt in line with broader policy guidance and evolving market conditions to help manage any potential impacts.

Looking ahead, sustained economic stability, supportive fiscal policies together with continued review of current regulations to bring them in line with international practices are extremely vital for the health of the pharmaceutical industry. Our commitment to operational excellence, strategic investments, and maintaining a strong balance sheet will be key drivers of our success as we navigate both prevalent opportunities and challenges.



Syed Anis Ahmed
Chief Executive



Ehsan Ali Malik
Director

ڈائریکٹرز رپورٹ

ڈائریکٹرز آپ کی کمپنی کے 30 ستمبر 2026 کو ختم ہونے والی نو ماہی کے ساتھ ساتھ 30 ستمبر 2026 کو ختم ہونے والی تیسری سہ ماہی کے لیے غیر آڈٹ شدہ عبوری مالی گوشوارے پیش کرتے ہوئے خوشی محسوس کرتے ہیں۔

مالی جھلکیاں

30 ستمبر 2026 کو ختم ہونے والی نو ماہی کیلئے

گزشتہ سال کی اسی مدت کے مقابلے میں سیلز میں 4 فیصد اضافہ ہوا۔ فارماسیوٹیکل سیلز میں 7 فیصد اضافہ ہوا جس کی وجہ سے قائم برانڈز کی مسلسل کارکردگی ہے نیوٹریشنز کی فروخت میں 5 فیصد کمی ہوئی جبکہ ڈاگناٹکس سیکٹ میں گزشتہ سال کے اسی عرصے کے مقابلے میں 9 فیصد اضافہ ہوا۔

اس مدت کے دوران آپ کی کمپنی کے مجموعی منافع کا مارجن پچھلے سال کی اسی مدت کے مقابلے میں 34 فیصد سے بڑھ کر 38 فیصد ہو گیا، جو بنیادی طور پر قیمتوں میں ایڈجسٹمنٹ اور پوری کمپنی میں اٹھائے گئے مختلف دیگر کارکردگی کے اقدامات اور مصنوعات کے امتزاج کی وجہ سے ہے۔ فارماسیوٹیکل طبقہ کے لیے مجموعی مارجن 33 فیصد سے بڑھ کر 39 فیصد ہو گیا، جبکہ نیوٹریشنز کے طبقے کے لیے مجموعی مارجن پچھلے سال کی اسی مدت کے مقابلے میں 44 فیصد سے کم ہو کر 41 فیصد ہو گیا۔

فروخت اور تقسیم کے اخراجات میں گزشتہ سال کے اسی عرصے کے مقابلے میں 6 فیصد اضافہ ہوا، جس کی بنیادی وجوہات کاروباری سرگرمیوں میں اضافہ اور مہنگائی کے اثرات تھے بہتر مارجنز کی وجہ سے ٹیکس کے اخراجات میں اضافہ ہوا۔ اس مدت کے دوران، فروخت کے تناسب سے خالص منافع 11 فیصد رہا۔

30 ستمبر 2026 کو ختم ہونے والی تیسری سہ ماہی کیلئے

گزشتہ سال کی اسی مدت کے مقابلے میں سہ ماہی کے لیے سیلز میں 4 فیصد اضافہ ہوا۔ فارماسیوٹیکل سیلز میں 5 فیصد اضافہ ہوا جبکہ نیوٹریشنز کی فروخت میں 2 فیصد کمی ہوئی۔

سال کے اب تک کے نتائج کی طرح مذکورہ وجوہات کی بناء پر کمپنی کے مجموعی منافع کا مارجن گزشتہ سال کی اسی مدت میں 34 فیصد سے بڑھ کر 38 فیصد ہو گیا۔

پریٹنگ اخراجات گزشتہ سال کے اسی عرصے کے مقابلے میں 2 فیصد کم رہے۔ اس کی بڑی وجہ عالمی سفری مسائل کے باعث سفر اور آمدورفت کے اخراجات میں کمی تھی۔ گزشتہ سال کی اسی سہ ماہی کے مقابلے میں دیگر اخراجات 63 ملین روپے (11 فیصد) بڑھ گئے۔ اس اضافے کی وجہ بہتر منافع ہونے کے باعث سرکاری اور قانونی فیسوں اور واجبات میں اضافہ تھا۔

نتیجتاً، سہ ماہی کے لیے ٹیکس کے بعد منافع میں گزشتہ سال کی اسی مدت کے مقابلے میں 721 ملین روپے کا اضافہ ہوا۔

مستقبل کا منظر نامہ

کمپنی اب بھی ریگولیٹری، مالیاتی اور مجموعی معاشی ماحول میں مسلسل تبدیلیوں کا سامنا کر رہی ہے، جس کے پیش نظر کمپنی نے اپنی حکمت عملی اور عملی اقدامات میں لچک اور تیزی برقرار رکھی ہے۔ کمپنی قومی ضروری ادویات کی فہرست میں شامل نہ ہونے والی ادویات سے متعلق حالیہ پالیسی تبدیلیوں کا خیر مقدم کرتی ہے۔ تاہم، لازمی ادویات کی قیمتوں کے باقاعدہ جائزے اور بروقت ایڈجسٹمنٹ کے لیے ایک مؤثر اور پائیدار طریقہ کار کی ضرورت بدستور برقرار ہے۔ اسی طرح، ہارڈشپ کیسز اور کم قیمت ادویات سے متعلق مسائل کے حتمی حل کو یقینی بنانا بھی ناگزیر ہے تاکہ مریضوں کو معیاری ادویات کی مسلسل اور بلا تعطل فراہمی برقرار رکھی جاسکے۔

موجودہ جغرافیائی و سیاسی کشیدگی کے باعث سال کی آخری سہ ماہی میں بھی کاروباری سرگرمیوں میں بعض رکاوٹوں کا امکان برقرار ہے۔ عالمی سطح پر تیل کی قیمتوں پر مسلسل دباؤ مہنگائی کے رجحانات میں مزید اضافہ کر سکتا ہے، جس کے نتیجے میں طلب متاثر ہونے اور زر مبادلہ کی صورت حال پر بھی دباؤ بڑھنے کا خدشہ ہے۔ کمپنی ان پیش رفتوں کا مسلسل جائزہ لے رہی ہے اور حکومتی پالیسیوں اور مارکیٹ کے بدلتے ہوئے حالات کے مطابق اپنی حکمت عملی اور اقدامات میں ضروری تبدیلیاں کر رہی ہے تاکہ ممکنہ منفی اثرات کو مؤثر انداز میں محدود کیا جاسکے۔

آئندہ کے تناظر میں، پائیدار معاشی استحکام، معاون مالیاتی پالیسیاں، اور موجودہ ضوابط کا بین الاقوامی بہترین طریقہ کار کے مطابق مسلسل جائزہ اور اصلاحات، دواسازی کی صنعت کی ترقی اور پائیداری کے لیے انتہائی اہم ہیں۔ آپریشنل عمدگی، اسٹریٹجک سرمایہ کاری، اور مضبوط مالی بنیاد کے فروغ کے لیے ہماری غیر متزلزل وابستگی، مستقبل میں درپیش مواقع سے مؤثر استفادہ کرنے اور چیلنجز سے کامیابی کے ساتھ نمٹنے میں بنیادی کردار ادا کرتی رہے گی۔


ڈائریکٹر


چیف ایگزیکٹو

کراچی 27 اکتوبر 2026

Condensed Interim Statement of Financial Position

As at September 30, 2026

	Note	September 30, 2026 (Un-audited)	September 30, 2025 (Audited)
----- Rupees in '000 -----			
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	6	16,242,572	15,635,851
Intangible assets		672	831
Long-term loans and advances		158,487	141,175
Long-term deposits		32,713	32,628
Long-term prepayments		15,618	12,395
		<u>16,450,062</u>	<u>15,822,880</u>
CURRENT ASSETS			
Stores and spares		670,358	669,690
Stock-in-trade	7	15,832,400	12,447,838
Trade debts		2,948,974	2,820,530
Loans and advances	8	1,143,123	399,086
Trade deposits and short-term prepayments	9	459,926	313,552
Other receivables	10	1,467,912	1,005,069
Taxation - net		806,912	-
Cash and cash equivalents	11	10,374,526	13,337,551
		<u>33,704,131</u>	<u>30,993,316</u>
TOTAL ASSETS		<u>50,154,193</u>	<u>46,816,196</u>
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Authorised capital		2,000,000	2,000,000
200,000,000 ordinary shares of Rs.10 each			
Issued, subscribed and paid-up capital	12	979,003	979,003
Reserves			
Capital		2,445,954	2,073,901
Revenue		31,340,723	28,572,553
		<u>33,786,677</u>	<u>30,646,454</u>
		<u>34,765,680</u>	<u>31,625,457</u>
NON-CURRENT LIABILITIES			
Deferred taxation - net		1,280,717	989,965
Staff retirement benefits		435,011	494,943
Lease liabilities		309,899	329,677
		<u>2,025,627</u>	<u>1,814,585</u>
CURRENT LIABILITIES			
Trade and other payables	13	12,387,316	12,198,722
Unclaimed dividends		123,122	71,155
Unpaid dividends		-	-
Taxation - net		-	246,958
Current maturity of lease liabilities		90,899	158,301
Provisions		761,549	701,018
		<u>13,362,886</u>	<u>13,376,154</u>
CONTINGENCIES AND COMMITMENTS	14		
TOTAL EQUITY AND LIABILITIES		<u>50,154,193</u>	<u>46,816,196</u>

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Condensed Interim Statement of Profit or Loss (Un-Audited)

For the nine months and three months ended September 30, 2026

	Nine Months Ended		Three Months Ended	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
Note	----- Rupees in '000 -----			
SALES - NET				
Local	57,135,984	53,909,372	19,985,118	18,995,527
Export	1,520,309	2,317,551	644,624	823,607
	58,656,293	56,226,923	20,629,742	19,819,134
Cost of sales	(36,442,164)	(36,886,086)	(12,865,719)	(13,093,197)
Gross Profit	22,214,129	19,340,837	7,764,023	6,725,937
Selling and distribution expenses	(9,042,285)	(8,501,410)	(2,859,975)	(2,974,143)
Administrative expenses	(1,099,517)	(972,482)	(384,932)	(334,287)
Other charges	(1,364,068)	(1,256,699)	(476,660)	(430,365)
Other income	745,997	603,335	176,614	186,590
	(10,759,873)	(10,127,256)	(3,544,953)	(3,552,205)
	11,454,256	9,213,581	4,219,070	3,173,732
Finance costs	(51,788)	(55,363)	(16,145)	(17,659)
Profit before taxation	11,402,468	9,158,218	4,202,925	3,156,073
Minimum tax differential		(146,989)	159,446	(146,989)
	11,402,468	9,011,229	4,362,371	3,009,084
Income tax				
Current	(4,455,086)	(3,828,736)	(1,379,231)	(1,181,163)
- For the year	27,553	-	27,553	-
- Prior year	(290,753)	183,225	(466,742)	(5,375)
Deferred	(4,718,286)	(3,645,511)	(1,818,420)	(1,186,538)
Net profit for the period	6,684,182	5,365,718	2,543,951	1,822,546
Basic and diluted earnings per share				
(Rs. per share)	68.28	54.81	25.99	18.62

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Abbott Pakistan

Condensed Interim Statement of Comprehensive Income (Un-Audited)

For the nine months and three months ended September 30, 2026

	Nine Months Ended		Three Months Ended	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
	----- Rupees in '000 -----			
Profit for the period	6,684,182	5,365,718	2,543,951	1,822,546
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	6,684,182	5,365,718	2,543,951	1,822,546

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



Chief Executive Officer



Director



Chief Financial Officer

Condensed Interim Statement of Cash Flows

(Un-Audited)

For the nine months ended September 30, 2026

		September 30, 2026	September 30, 2025
Note		----- Rupees in '000 ----- (Un-audited)	(Audited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	8,193,013	9,020,548
Income taxes paid		(5,481,404)	(3,748,060)
Long-term loans and advances - net		(17,312)	(15,011)
Long-term deposits - net		(85)	(25,200)
Long-term prepayments - net		(3,223)	3,632
Contributions to staff retirement benefit funds		(287,674)	(253,147)
Net movement in provisions		60,531	61,942
Net cash inflow from operating activities		2,463,846	5,044,704
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to operating fixed assets and CWIP	6.1	(2,117,451)	(1,893,111)
Sale proceeds from disposal of property, plant and equipment		70,758	177,968
Interest income		622,835	345,737
Net cash outflow from investing activities		(1,423,858)	(1,369,406)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance costs paid		(6,334)	(7,571)
Lease rentals paid		(132,634)	(79,131)
Dividends paid		(3,864,045)	(761,399)
Net cash outflow from financing activities		(4,003,013)	(848,101)
Net increase / (decrease) in cash and cash equivalents		(2,963,025)	2,827,197
Cash and cash equivalents at beginning of the period		13,337,551	6,182,349
Cash and cash equivalents at end of the period	17.2	10,374,526	9,009,546

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Condensed Interim Statement of Changes in Equity (Un-Audited)

For the nine months ended September 30, 2026

Share Capital	Reserves					Total Equity
	Capital Reserves		Revenue Reserves		Total	
	Reserve arising on Merger	Other	General Reserve	Un-appropriated Profit		

----- Rupees in '000 -----

Balance as at January 1, 2025 (Audited) 979,003 46,097 1,704,384 5,338,422 15,656,730 22,745,633 23,724,636

Final dividend for the year ended December 31, 2024 @ Rs 10.0 per share - - - - (979,003) (979,003) (979,003)

Employee benefit cost under IFRS 2 - 'Share based payments' - - 243,476 - - 243,476 243,476

**Total comprehensive income for the period ended
September 30, 2025**

Net profit for the period	-	-	-	-	5,365,718	5,365,718	5,365,718
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	5,365,718	5,365,718	5,365,718

Balance as at September 30, 2025 (Un-audited) 979,003 46,097 1,947,860 5,338,422 20,043,445 27,375,824 28,354,827

Balance as at January 01, 2026 (Audited) 979,003 46,097 2,027,804 5,338,422 23,234,131 30,646,454 31,625,457

Final dividend for the year ended December 31, 2024 @ Rs. 10/- per share - - - - (3,916,012) (3,916,012) (3,916,012)

Employee benefit cost under IFRS 2 - 'Share based payments' - - 372,053 - - 372,053 372,053

**Total comprehensive income for the period ended
September 30, 2026**

Net profit for the period	-	-	-	-	6,684,182	6,684,182	6,684,182
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	6,684,182	6,684,182	6,684,182

Balance as at Septmeber 30, 2026 (Un-audited) 979,003 46,097 2,399,857 5,338,422 26,002,301 33,786,677 34,765,680

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2026

1 THE COMPANY AND ITS OPERATIONS

Abbott Laboratories (Pakistan) Limited (the Company) is a public limited Company incorporated in Pakistan on July 02, 1948, and its shares are quoted on Pakistan Stock Exchange. The address of its registered office is Plot No. 258 & 324, opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.

2. STATEMENT OF COMPLIANCE

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 - 'Interim Financial Reporting', issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

3. BASIS OF PREPARATION

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting and notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. These condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2025.

These condensed interim financial statements are presented in Pakistan Rupees, which is the Company's functional and presentation currency.

4. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS

There are certain amendments to existing accounting and reporting standards that have become applicable to the Company for accounting periods beginning on or after January 01, 2026. These are either considered to not be relevant or do not have any significant impact and accordingly, have not been detailed in these condensed interim financial statements.

5. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND FINANCIAL RISK MANAGEMENT

The preparation of condensed interim financial statements in conformity with approved accounting standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Judgements and estimates made by the management in the preparation of these condensed interim financial statements are the same as those applied in the Company's annual financial statements for the year ended December 31, 2025.

The Company's financial risk management objectives and policies are consistent with those disclosed in the annual financial statements as at and for the year ended December 31, 2025.

		September 30, 2026	December 31, 2025
Note		---- Rupees in '000 ---- (Un-audited)	(Audited)

6. PROPERTY, PLANT AND EQUIPMENT

Operating fixed assets	6.1, 6.2	13,543,948	12,896,046
Capital work-in-progress	6.1	2,359,684	2,312,909
Right-of-use assets	6.3	338,940	426,896
		<u>16,242,572</u>	<u>15,635,851</u>

- 6.1 Following were the additions and disposals of operating fixed assets and capital work-in-progress during the period:

	Additions	Disposals	
	Cost		Accumulated Depreciation
	----- Rupees in '000 -----		
Plant and Machinery	583,185	37,001	33,403
Vehicles	486,599	95,582	62,675
Computers	131,599	50,070	50,056
Office Equipment	287,988	465	442
Furniture & Fixture	-	2,506	2,281
Service equipment	581,816	5,156	5,156
Capital work-in-progress - net additions	46,775	-	-
	<u>2,117,962</u>	<u>190,780</u>	<u>154,013</u>

- 6.2 Depreciation charge for the period ended September 30, 2026 amounting to Rs. 1,386 million (September 30, 2025: Rs. 1,685 million).

6.3 Right-of-use assets

		September 30, 2026	December 31, 2025
Note		---- Rupees in '000 ---- (Un-audited)	(Audited)
Warehouses, sales offices and city office	6.3.1	<u>338,940</u>	<u>426,896</u>

- 6.3.1 Depreciation charge for the period ended September 30, 2026 amounted to Rs. 88 million (September 30, 2025: Rs. 95 million).

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2026

7. STOCK-IN-TRADE

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
Raw and packing materials [including stock-in-transit of Rs. 1,890 million (December 31, 2025: Rs.980 million)]		8,075,965	5,982,237
Work-in-process		629,814	500,780
Finished goods [including stock-in-transit of Rs. 968 million (December 31, 2025: Rs.432 million)]"	7.1	7,724,519	6,432,464
		16,430,298	12,915,481
Less: provision for slow moving and obsolete items		(597,898)	(467,643)
		15,832,400	12,447,838

- 7.1 Stock-in-trade includes items costing Rs. 803 million (December 31, 2025: Rs. 1,147 million) valued at net realisable value of Rs. 547 million (December 31, 2025: Rs. 863 million) resulting in a write down of Rs. 256 million (December 31, 2025: Rs. 265.332 million)

8. LOANS AND ADVANCES

Represent loans and advances amounted to Rs. 73 million and Rs. 1,070 million (December 31, 2025: Rs. 65 million and Rs. 334 million), respectively, net of allowance.

9. TRADE DEPOSITS AND SHORT-TERM PREPAYMENTS

Represent trade deposits and short-term prepayments amounted to Rs. 302 million and Rs. 158 million (December 31, 2025: Rs. 361 million and Rs. 195 million), respectively, net of allowance.

10. OTHER RECEIVABLES

Includes sales tax receivable and due from related parties amounting to Rs. 782 million and Rs. 12 million (December 31, 2025: Rs. 485 million and Rs. 197 million), respectively.

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
11. CASH AND BANK BALANCES			
With banks			
Saving accounts:			
- local currency	11.1	8,563,983	11,590,605
Current accounts:			
- local currency		104,257	116,911
- foreign currency		1,700,846	1,624,563
		1,805,103	1,741,474
In hand			
- local currency		987	4,519
- foreign currency		4,453	953
		5,440	5,472
		10,374,526	13,337,551

- 11.1 These saving accounts carry mark-up at the rate of 4% to 10% (December 31, 2025: 4% to 9.50%) per annum.

12. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at September 30, 2026, Abbott Asia Investments Limited, UK (the Holding Company) held 76,259,454 (December 31, 2025: 76,259,454) shares. The ultimate holding company is Abbott Laboratories, USA.

13. TRADE AND OTHER PAYABLES

Includes accrued liabilities amounted to Rs. 8,977 million (December 31, 2025: Rs. 6,190 million), bills payable of Rs. 2,910 million (December 31, 2024: Rs. 2,924 million).

14. CONTINGENCIES AND COMMITMENTS

- 14.1 The Company is defending various minor suits filed against it in various courts in Pakistan related to its business operations as at reporting date, which are not material to disclose as contingencies. The Company's management is confident, based on the advice of its legal advisors, that these suits will be decided in the Company's favour.

14.2 Commitments

- 14.2.1 Commitments for capital expenditure as at September 30, 2026, aggregated to Rs. 957 million (December 31, 2025: Rs. 876 million).

- 14.2.2 Commitments in respect of letters of credit as at September 30, 2026 aggregated to Rs.1,415 million (December 31, 2025: Rs. 1,934 million)."

- 14.2.3 The Company has given bank guarantees as at September 30, 2026 of Rs. 284,304 million (December 31, 2025: 473 million) to the Customs Department, a utility company and other institutions against tenders.

- 14.2.4 The Company has obtained short-term financing facilities from various commercial banks amounting to Rs. 8,100 million (2025: Rs. 7,600 million). These facilities can be utilised for letters of credit, guarantees and running finance / short-term loans. These include short-term financing facilities obtained from Standard Chartered Bank (Pakistan) Limited (a related party) amounting to Rs. 2,900 million (2025: Rs. 2,900 million) and from Habib Metropolitan Bank Limited (a related party) amounting to Rs. 1,500 million (2025: Rs. 1,500 million). However, the running finance / short-term loan utilisation cannot exceed Rs. 4,790 million (2025: Rs. 4,290 million). The running finance / short-term loan carries markup at rates ranging from KIBOR minus 0.25% to flat KIBOR (2025: KIBOR minus 0.25% to flat KIBOR) per annum and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not utilised any amount against running finance / short-term loan facilities neither pledged its inventory as at the reporting date.

15. OTHER CHARGES

	Nine months ended September 30, 2026 ---- Rupees in '000 ---- (Un-audited)	Nine months ended September 30, 2025 ---- Rupees in '000 ---- (Un-audited)
Exchange loss - net	80,892	164,174
Workers' Profit Participation Fund	612,757	492,570
Workers' Welfare Fund	239,927	200,618
Central Research Fund	125,479	92,507
Donations	34,157	17,500
Auditors' remuneration	9,598	11,019
Provision for expected credit loss on trade debts	260,204	277,941
Provision for expected credit loss on other receivables	1,054	370
	1,364,068	1,256,699

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2026

Note	Nine months ended September 30, 2026 ---- Rupees in '000 ---- (Un-audited)	Nine months ended September 30, 2025 ---- (Audited)
------	---	--

16. OTHER INCOME

Income from financial assets

- term deposit receipts	-	-
- saving accounts	622,835	345,737
	622,835	345,737

Income from non-financial instruments

Gain on disposal of property, plant and equipment - net	33,993	99,788
Exchange gain - net	-	-
Reversal of expected credit losses on trade debts	-	-
Scrap sales	77,744	49,435
Waiver of liability	-	-
Others	11,425	108,375
	123,162	257,598
	745,997	603,335

17. CASH GENERATED FROM OPERATIONS

Profit before taxation	11,402,468	9,158,218
------------------------	------------	-----------

Adjustment for non-cash changes and other items:

Depreciation of operating fixed assets	1,386,007	1,684,833
Depreciation of right-of-use assets	87,958	94,746
Amortisation of intangible assets	159	366
Provision / (reversal) for slow moving and obsolete stock in trade	130,255	140,459
Provision allowance for expected credit losses on trade debts	260,204	277,941
Allowance for expected credit losses on other receivables	1,055	370
Gain on disposal of property, plant and equipment	(33,993)	(99,788)
Interest income	(622,835)	(345,737)
Expense recognized in profit or loss in respect of equity-settled shared-based compensation	372,053	243,476
Staff retirement benefits	227,742	299,759
Finance costs	51,788	55,363
Working capital changes	17.1 (5,069,848)	(2,489,458)
	8,193,013	9,020,548

17.1 Working capital changes

(Increase) / decrease in current assets

Stores and spares	(668)	(40,819)
Stock-in-trade	(3,514,817)	(2,963,017)
Trade debts	(388,648)	(685,815)
Loans and advances	(744,037)	(109,152)
Trade deposits and short-term prepayments	(146,374)	(271,768)
Other receivables	(463,898)	(148,258)
	(5,258,442)	(4,218,829)

Increase in current liabilities

Trade and other payables	188,594	1,729,371
	(5,069,848)	(2,489,458)

17.2 Cash and cash equivalents

Cash and bank balances	11 10,374,526	9,009,546
Term deposit receipts	-	-
	10,374,526	9,009,546

18. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise the holding company, ultimate holding company, group companies, employee retirement benefit plans, directors and key management personnel. All the transactions with related parties are entered into at agreed terms in the normal course of business as approved by the Board of Directors of the Company. Transactions with related parties during the period are as follows:

	Nine months ended September 30, 2026 ---- Rupees in '000 ---- (Un-audited)	Nine months ended September 30, 2025 ---- Rupees in '000 ---- (Un-audited)
Holding Company		
Dividend paid	<u>3,050,378</u>	<u>476,622</u>
Group companies		
Sale of goods	<u>1,310,272</u>	<u>766,910</u>
Purchase of stock-in-trade	<u>13,083,942</u>	<u>13,845,139</u>
Technical service fee	<u>305,190</u>	<u>271,924</u>
Reimbursement of expenses - net	<u>533,639</u>	<u>510,398</u>
Other income	<u>11,425</u>	<u>108,375</u>
Retirement fund:		
- Contribution to Pension fund	<u>216,717</u>	<u>200,597</u>
- Contribution to Provident fund	<u>155,279</u>	<u>134,449</u>
- Contribution to Gratuity fund	<u>71,390</u>	<u>54,348</u>
Key management personnel		
Remuneration and other short-term employee benefits	<u>429,982</u>	<u>618,006</u>
Post-employment benefits	<u>54,730</u>	<u>49,175</u>

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2026

19. SEGMENT ANALYSIS

19.1 Segment wise operating results for nine months ended (Un-audited):

	September 30, 2026					September 30, 2025				
	Pharmaceutical	Nutritional	Diagnostic	Others	Total	Pharmaceutical	Nutritional	Diagnostic	Others	Total
Rupees in '000										
Sales	45,076,221	14,582,988	4,830,270	1,688,907	66,178,386	42,163,391	15,341,992	4,747,227	1,616,640	63,869,250
Less:										
Sales return	204,709	53,226	31,856	2,146	291,937	62,028	53,083	322,733	9,912	447,756
Trade discounts	2,863,839	771,542	-	61,683	3,697,064	2,780,360	833,012	-	52,890	3,666,262
Sales tax and excise duty	411,566	2,329,395	633,466	158,664	3,533,091	372,497	2,411,874	590,011	153,927	3,528,309
Sales - net	41,596,107	11,428,825	4,164,948	1,466,414	58,656,294	38,948,506	12,044,023	3,834,483	1,399,911	56,226,923
Cost of sales	(25,272,542)	(6,709,009)	(3,575,211)	(885,403)	(36,442,165)	(26,013,849)	(6,747,956)	(3,220,290)	(903,991)	(36,886,086)
Gross profit	16,323,565	4,719,816	589,737	581,011	22,214,129	12,934,657	5,296,067	614,193	496,920	19,340,837
Selling and distribution expenses	(6,126,560)	(2,302,746)	(356,430)	(256,549)	(9,042,285)	(5,801,555)	(2,068,544)	(407,832)	(223,479)	(8,501,410)
Administrative expenses	(959,890)	(133,730)	(5,887)	-	(1,099,517)	(822,188)	(122,330)	(27,964)	-	(972,482)
Segment result	9,237,115	2,283,340	227,410	324,462	12,072,327	6,310,914	3,105,193	178,397	272,441	9,866,945

19.2 Segment wise operating results for the third quarter (Un-audited):

	September 30, 2026					September 30, 2025				
	Pharmaceutical	Nutritional	Diagnostic	Others	Total	Pharmaceutical	Nutritional	Diagnostic	Others	Total
Rupees in '000										
Sales	15,932,838	5,209,971	1,612,287	568,340	23,323,436	15,084,755	5,265,050	1,698,013	465,311	22,513,129
Less:										
Sales return	38,963	12,424	7,119	595	59,101	30,047	20,796	139,607	1,767	192,217
Trade discounts	1,070,929	274,286	-	21,412	1,366,627	998,951	283,794	-	15,151	1,297,896
Sales tax and excise duty	145,173	855,445	213,610	53,737	1,267,965	132,913	828,874	201,011	41,084	1,203,882
Sales - net	14,677,773	4,067,816	1,391,558	492,596	20,629,743	13,922,844	4,131,586	1,357,395	407,309	19,819,134
Cost of sales	(8,999,048)	(2,467,005)	(1,128,755)	(270,912)	(12,865,720)	(9,528,439)	(2,186,326)	(1,122,371)	(256,061)	(13,093,197)
Gross profit	5,678,725	1,600,811	262,803	221,684	7,764,023	4,394,405	1,945,260	235,024	151,248	6,725,937
Selling and distribution expenses	(2,063,262)	(677,150)	(48,903)	(70,660)	(2,859,975)	(2,181,372)	(634,469)	(106,101)	(52,201)	(2,974,143)
Administrative expenses	(333,913)	(48,211)	(2,808)	-	(384,932)	(286,442)	(42,615)	(5,230)	-	(334,287)
Segment result	3,281,550	875,450	211,092	151,024	4,519,116	1,926,591	1,268,176	123,693	99,047	3,417,507

19.3 Reconciliation of segment results with profit before taxation (Un-audited)

	Nine Months Ended		Quarter Ended	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
Rupees in '000				
Total segment results	12,072,327	9,866,945	4,519,116	3,417,507
Other income	745,997	603,335	176,614	186,590
Other charges	(1,364,068)	(1,256,699)	(476,660)	(430,365)
Finance costs	(51,788)	(55,363)	(16,145)	(17,659)
Profit before taxation	11,402,468	9,158,218	4,202,925	3,156,073

19.4 Geographical information (Un-audited)

	Nine Months Ended		Quarter Ended	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
	----- Rupees in '000 -----			
Sales to external customers, net of returns, discounts, sales tax and excise duty				
Pakistan	57,135,984	47,273,134	19,985,118	18,995,527
Afghanistan	167,593	1,277,592	-	278,644
Sri Lanka	6,751	25,483	6,751	10,477
Bangladesh	35,692	60,125	-	20,775
Switzerland	1,310,272	927,745	637,873	270,649
	<u>58,656,292</u>	<u>49,564,079</u>	<u>20,629,742</u>	<u>19,576,072</u>

19.5 Segment Assets and Liabilities

Unaudited					
Sep 30, 2026					
Pharmaceutical	Nutritional	Diagnostics	Others	Total	
----- Rupees in '000 -----					
Segment assets employed	26,479,734	2,737,892	7,965,639	282,739	37,466,004
Unallocated corporate assets					12,688,189
Total assets					50,154,193
Segment liabilities	9,041,593	1,330,490	1,327,958	66,996	11,767,037
Unallocated corporate liabilities					3,621,476
Total liabilities					15,388,513

Audited					
December 31, 2025					
Pharmaceutical	Nutritional	Diagnostics	Others	Total	
----- Rupees in '000 -----					
Segment assets employed	23,266,838	2,329,347	6,984,562	290,397	32,871,144
Unallocated corporate assets					13,945,052
Total assets					46,816,196
Segment liabilities	9,941,693	799,701	1,614,756	32,875	12,389,025
Unallocated corporate liabilities					2,801,714
Total liabilities					15,190,739

20. DATE OF AUTHORISATION

These condensed interim financial statements were authorised for issue on October 27, 2026 by the Board of Directors of the Company.



Chief Executive Officer



Director



Chief Financial Officer

life. to the fullest.®



ABBOTT